Northwestern Medicine investigators have identified a previously unknown regulator of tumor immune evasion, which may help improve the efficacy of current and future anti-tumor immunotherapies, according to recent findings published in the Journal of Clinical Investigation.
“The study provides a molecular insight into understanding why some cancer patients cannot be treated by the checkpoint blockade antitumor therapy, but others can,” said Deyu Fang, Ph.D., the Hosmer Allen Johnson Professor of Pathology and senior author of the study.
Antitumor immunotherapy is a type of cancer treatment that helps the immune system in fighting cancer and includes a range of therapy types, such as immune checkpoint inhibitors. Immune checkpoints help prevent the immune system from being too strong and eradicating other cells, including cancer cells.
Leave a reply